Literature DB >> 9646775

Prophylaxis of deep venous thrombosis and pulmonary embolism. Current recommendations.

R D Hull1, G F Pineo.   

Abstract

Pulmonary embolism is responsible for approximately 150,000 to 200,000 deaths per year in the United States. Venous thromboembolism usually occurs as a complication in patients who are sick and hospitalized, but it may also affect ambulant and otherwise healthy individuals. Many patients who die from pulmonary embolism succumb suddenly or within 2 hours after the acute event (i.e., before therapy can be initiated or take effect). Therefore, prevention is the key to reducing death and morbidity from venous thromboembolism. Effective and safe prophylactic measures against venous thromboembolism are now available for most high-risk patients. This article highlights practical approaches to the prevention of venous thromboembolism.

Entities:  

Mesh:

Year:  1998        PMID: 9646775     DOI: 10.1016/s0025-7125(05)70006-7

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  4 in total

Review 1.  A systematic review of mobility/immobility in thromboembolism risk assessment models for hospitalized patients.

Authors:  Fan Ye; Carolyn Stalvey; Matheen A Khuddus; David E Winchester; Hale Z Toklu; Joseph J Mazza; Steven H Yale
Journal:  J Thromb Thrombolysis       Date:  2017-07       Impact factor: 2.300

Review 2.  Deep venous thrombosis prophylaxis in patients with heart disease.

Authors:  B K Shively
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 2.931

3.  Deep venous thrombosis caused by congenital absence of the inferior vena cava: report of a case.

Authors:  Yuka Kondo; Jun Koizumi; Masayasu Nishibe; Akihito Muto; Alan Dardik; Toshiya Nishibe
Journal:  Surg Today       Date:  2009-03-12       Impact factor: 2.549

Review 4.  Proficient and cost-effective approaches for the prevention and treatment of venous thrombosis and thromboembolism.

Authors:  R L Bick
Journal:  Drugs       Date:  2000-09       Impact factor: 11.431

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.